Rebound Therapeutics Finds $16.5M

Irvine-based Rebound Therapeutics announced today that it has raised $16.5M in a Series B funding, for the company's development of devices used for recovery from minimally invasive surgery. According to Rebound, the funding was led by HBM-MedFocus, and also included Invus Opportunities Fund and affiliates of Wexford Capital LP. Rebound said the new funds will go towards ongoing product development, worldwide regulatory approvals, manufacturing scale-up and commercialization efforts. Rebound's President and CEO is Jeffrey Valko.